Comorbid cancer and systemic therapy may influence immune response to SARS-CoV-2 among patients and health care workersYuchen Dai -
1. In this cross-sectional study of Japanese patients with cancer and health care workers, the seroprevalence of SARS-CoV-2 antibodies did not differ between the two cohorts. 2. However, results suggest that comorbid cancer and treatment with systemic therapy, including chemotherapy and immune checkpoint inhibitors, may be associated with differences in...
#VisualAbstract: Lobaplatin-based induction chemotherapy is safe and efficacious for patients with advanced nasopharyngeal carcinomasTeddy Guo -
Click to read the study in The Lancet Oncology.